Cargando…

COVID-19: coagulation disorders and anticoagulant treatment in patients hospitalised in ICU

Patients hospitalized in the intensive care unit (ICU) due to the COVID-19 experience a high incidence (up to 43%) of venous thromboembolic events. While laboratory findings in COVID-19-associated coagulopathy (CAC) show increased D-dimer and fibrinogen levels, the abnormalities in standard coagulat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pluta, Jan, Trzebicki, Agnieszka Cieniewicz Janusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2021
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158437/ https://www.ncbi.nlm.nih.gov/pubmed/34006056 http://dx.doi.org/10.5114/ait.2021.105783

Ejemplares similares

Malignant hyperthermia in Mazovia Province – are we adequately prepared?
por: Cieniewicz, Agnieszka, et al.
Publicado: (2022)

Malignant hyperthermia in Poland: A survey study
por: Cieniewicz, Agnieszka, et al.
Publicado: (2023)

DIC, SIC or CAC – the haemostatic profile in COVID-19 patients hospitalised in the intensive care unit: a single-centre retrospective analysis
por: Pluta, Jan, et al.
Publicado: (2021)

Coagulation and anticoagulation in COVID-19
por: Hadid, Tarik, et al.
Publicado: (2021)

Assessment of haemostasis and impact of fibrinogen supplementation on clot properties using global haemostasis assays in patients on chronic dialysis
por: Pluta, Jan, et al.
Publicado: (2020)

Anticoagulation as a therapeutic strategy for hospitalised patients with COVID-19
por: Cullivan, S., et al.
Publicado: (2022)

Cochrane Corner: The use of anticoagulants in patients hospitalised with COVID-19
por: Gloeck, N, et al.
Publicado: (2023)

Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19
por: Bowles, Louise, et al.
Publicado: (2020)

Coagulation profile of COVID-19 patients admitted to the ICU: An exploratory study
por: Corrêa, Thiago Domingos, et al.
Publicado: (2020)

Coagulation and anticoagulation in idiopathic pulmonary fibrosis
por: Crooks, Michael G., et al.
Publicado: (2015)

Major coagulation disorders and parameters in COVID-19 patients
por: Teimury, Azadeh, et al.
Publicado: (2022)

Coagulation assessment with the new generation of oral anticoagulants
por: Pollack, Charles V
Publicado: (2016)

Risk Management and Treatment of Coagulation Disorders Related to COVID-19 Infection
por: Zanza, Christian, et al.
Publicado: (2021)

Safety and Efficacy of Intermediate- and Therapeutic-Dose Anticoagulation for Hospitalised Patients with COVID-19: A Systematic Review and Meta-Analysis
por: Reis, Stefanie, et al.
Publicado: (2021)

Coagulation System Activation for Targeting of COVID-19: Insights into Anticoagulants, Vaccine-Loaded Nanoparticles, and Hypercoagulability in COVID-19 Vaccines
por: Abdel-Bakky, Mohamed S., et al.
Publicado: (2022)

New oral anticoagulants: are coagulation units still required?
por: Altman, Raul
Publicado: (2014)

Prominent coagulation disorder is closely related to inflammatory response and could be as a prognostic indicator for ICU patients with COVID-19
por: Liu, Yang, et al.
Publicado: (2020)

Dysregulated Neutrophil Phenotype and Function in Hospitalised Non-ICU COVID-19 Pneumonia
por: Belchamber, Kylie B. R., et al.
Publicado: (2022)

Coagulation disorders and vascular diseases of the liver in patients with COVID-19
por: Tsafaridou, Maria, et al.
Publicado: (2022)

In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID‐19 patients on anticoagulation
por: Blasi, Annabel, et al.
Publicado: (2020)

Coagulation disorder in COVID-19
por: Kander, Thomas
Publicado: (2020)

Real World Outcomes of Therapeutic Anticoagulation Use in Moderate COVID-19 Infection in Hospitalised Patients
por: Creeper, Katherine J., et al.
Publicado: (2022)

Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status
por: Antinori, Spinello, et al.
Publicado: (2020)

Safety and Efficacy of Different Anticoagulant Doses for Patients with COVID-19 in the ICU: A Systematic Review and Meta-Analysis
por: Rachina, Svetlana, et al.
Publicado: (2023)

Coagulation Disorders in COVID-19: Role of Toll-like Receptors
por: Biswas, Indranil, et al.
Publicado: (2020)

Coagulation Profile of COVID-19 Patients
por: Kaiafa, Georgia, et al.
Publicado: (2022)

Chronic anticoagulation is not associated with a reduced risk of acute kidney injury in hospitalised Covid-19 patients
por: Parker, Kathrine, et al.
Publicado: (2021)

Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring
por: Mueck, Wolfgang, et al.
Publicado: (2013)

Anticoagulant therapies against sepsis‐induced disseminated intravascular coagulation
por: Umemura, Yutaka, et al.
Publicado: (2023)

Anticoagulant Treatment in Severe ARDS COVID-19 Patients
por: Ceccato, Adrian, et al.
Publicado: (2022)

Causes and outcomes of ICU hospitalisations in patients with pulmonary arterial hypertension
por: Naranjo, Mario, et al.
Publicado: (2022)

Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy
por: Belen-Apak, F. Burcu, et al.
Publicado: (2020)

Coagulation Disorders in Sepsis and COVID-19—Two Sides of the Same Coin? A Review of Inflammation–Coagulation Crosstalk in Bacterial Sepsis and COVID-19
por: Tuculeanu, Georgeana, et al.
Publicado: (2023)

Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients
por: Zhang, Yan, et al.
Publicado: (2020)

Effect of Therapeutically Related Drugs on Coagulation-Anticoagulation Balance in Acute Promyelocytic Leukemia
por: Xiao, Mengyu, et al.
Publicado: (2022)

Crosstalk between Circulating Tumor Cells and Plasma Proteins—Impact on Coagulation and Anticoagulation
por: Wang, Yuanyuan, et al.
Publicado: (2023)

Chronic Subdural Hematoma, Caused by Disseminated Intravascular Coagulation and/or Anticoagulation Therapy, after COVID-19
por: NOMURA, Yu, et al.
Publicado: (2022)

Role of crotoxin in coagulation: novel insights into anticoagulant mechanisms and impairment of inflammation-induced coagulation
por: Gimenez, Bruna Terada, et al.
Publicado: (2020)

Correction of Anticoagulant Therapy in Patients with Severe COVID-19 Virus Infection Using a Thrombodynamics Coagulation Assay
por: Vuimo, Tatiana S., et al.
Publicado: (2022)

Thrombocytopenia and coagulation disorders due to COVID 19 infection with concomitant cardiovascular diseases requiring anti-platelet and anticoagulant therapy, which strategy?
por: Buioni, Dario, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_60p7vp3n4lu7jo70hbqv897q1v